Onderneming Cullinan Therapeutics, Inc.
Aandelen
CGEM
US2300311063
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
28,1 USD | +4,04% | +48,76% | +175,76% |
29/04 | Cullinan Therapeutics benoemt Mary Kay Fenton tot CFO | MT |
16/04 | Transcript : Cullinan Oncology, Inc. - Special Call |
Vakgebied
Aantal werknemers: 85
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 18-10-21 |
Jeffrey Jones
CTO | Chief Tech/Sci/R&D Officer | 53 | 28-02-22 |
Jacquelyn Sumer
CMP | Compliance Officer | 46 | 15-08-22 |
Chief Tech/Sci/R&D Officer | 57 | 01-01-18 | |
Kevin Johnston
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-22 |
Chad Messer
IRC | Investor Relations Contact | - | 01-03-22 |
Corinne Savill
PRN | Corporate Officer/Principal | 64 | 01-02-17 |
Stephen Andre
HRO | Human Resources Officer | 62 | 01-04-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 71 | 01-08-17 | |
Thomas Ebeling
BRD | Director/Board Member | 65 | 01-08-17 |
Stephen Webster
BRD | Director/Board Member | 63 | 01-09-20 |
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 18-10-21 |
Director/Board Member | 52 | 28-02-22 | |
David Ryan
BRD | Director/Board Member | 57 | 01-11-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 43 065 645 | 40 310 790 ( 93,60 %) | 0 | 93,60 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+175,76% | 1,16 mld. | |
+0,67% | 42,19 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+6,55% | 24,63 mld. | |
-21,66% | 18,2 mld. | |
+29,96% | 12,01 mld. | |
-1,57% | 11,76 mld. | |
+16,03% | 10,4 mld. | |
-4,80% | 9,94 mld. |
- Beurs
- Aandelen
- Koers CGEM
- Onderneming Cullinan Therapeutics, Inc.